Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer research hub

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.